BIOCHEMICAL SOCIETY TRANSACTIONS soma1 oxidase ( H 2 0 , production). Nevertheless, mitochondrial oxidation of sebacyl-carnitine could be recorded. This activity was 10-20% of that measured in the same mitochondrial preparation with palmitoyl-CoA ( + L-carnitine) or decanoyl-carnitine. Further, there was no indication of interference by sebacyl-CoA with carnitine palmitoyltransferase.
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In conclusion, intravenously infused dodecanedioic acid is readily catabolized in control rats in which less than 30% of the infused dose is recovered in urine as shorter dicarboxylates. Further experiments with radiolabelled dicarboxylates are necessary to determine the fate of the remaining 70%; the possibility exists that they are completely oxidized in mitochondria. Indeed, we showed by experiments in vitro that mitochondria are able to oxidize dicarboxyl-carnitine esters, although the mechanism of formation of these esters was not elucidated. Dicarboxyl-carnitine esters do not appear to be formed by mitochondrial carnitine palmitoyltransferase. Riboflavin deficiency, which induces a profound impairment of the activities of mitochondrial, but not of peroxisomal, flavoproteins and thus induces by itself a dicarboxylic aciduria, considerably increases the proportion of dicarboxylates recovered in urine from the infused dodecanedioic acid. The administration of clofibrate, a drug which, among other effects, stimulates both mitochondrial and peroxisomal poxidation in rats, strongly decreases the excretion of dicarboxylates in urine.
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It itrodir ction
During the last decade, several new inborn errors of mitochondrial and peroxisomal fatty acid oxidation have been described. These inborn errors of metabolism are likely to be much more common than has been recognized until now, and they may present in a variety of different ways. This review will be confined to the inborn errors of mitochondrial P-oxidation, and it will report the recent progress that has been made in the study of these disorders. Progress in understanding disorders of peroxisomal /?-oxidation has been described elsewhere (Fahimi & Sies, 1987) .
Investigutions of defects ofjutty ucid oxidution
The most important initial investigations to be performed in patients with suspected defects of fatty acid oxidation are the determination of the circulating blood concentrations of intermediary metabolites and of urinary organic acids. Hypoglycaemia, when associated with low blood ketone body concentrations and normal or high non-esterified fatty acid concentrations, strongly suggests that a defect of fatty acid oxidation is likely to be present. A defect of mitochondrial P-oxidation is often associated with the excretion of abnormal metabolites in the urine, and these metabolites can be detected by analysing the urine by gas chromatography, gas chromatography-mass spectrometry and high performance liquid chromatography. Thus, in the presence of a defect of mitochondrial fatty acid oxidation, long-chain fatty acids may be directed to w-oxidation which is followed by A. AYNSLEY-GREEN?
Abbreviations used: CPT, carnitine palmitoyltransferase; ETF, electron transfer flavoprotein; ETF-QO, electron transfer flavoprotein:ubiquinone oxidoreductase.
peroxisomal /%oxidation to form dicarboxylic acids that arc subsequently excreted (Van Hoof et ul.. 1988) . Moreover, the accumulation of acyl-CoA esters in the mitochondrial matrix is associated with the increased urinary excretion of acylcarnitines and glycine conjugates owing to the action o f carnitine acyltransferases and glycine-N-acylasc, respectively. These metabolites can be of substantial diagnostic value, thus for example, the presence of medium-chain dicarboxylic acids, suberylglycine and octanoylcarnitine. are very suggestive of medium-chain acyl-CoA dehydrogcnase deficiency (Bhuiyan et ul., 1987) . However, the urinary excretion of abnormal metabolites can be extremely variable. and some patients under non-stressed conditions may not excrete any abnormal metabolites. It is imperative, therefore, to obtain appropriate blood and urine samples when the patient has a spontaneous episode of illness. If this is not possible, then samples should be collected during metabolic stress induced by carefully controlled fasting in hospital. The starvation test is potentially very dangerous, particularly in childrep, and it should only be performed by individuals experienced in metabolic investigations. The next step in the investigation is to measure the flux through fatty acid oxidation either radiochemically or spectrophotometrically using cultured fibroblasts or tissues from the patient. If these investigations are abnormal, direct assay of the individual enzymes of B-oxidation is required.
Etizyme defects
There are 15 enzymes involved in the P-oxidation of saturated fatty acids and defects of seven of these have been described to date (see below). N o defects have yet been reported in patients of carnitine/acylcarnitine translocase. the enoyl-CoA hydratases, the hydroxyacyl-CoA dehydrogenases, the long-chain 3-oxoacyl-CoA thiolase or of the auxiliary enzymes required for the oxidation of polyunsaturated fatty acids. Carnitine deficiency has been discussed recently (Turnbull & Sherratt, 1985) . The syndromes in which enzyme deficiencies have been found will now be discussed.
C'artiirine pulmitoyltraw.~erase deficiency. Acyl-CoA esters cannot cross the inner mitochondrial membrane directly and are transported into the mitochondrial matrix by the concerted action of the enzymes carnitine palmitoyltransferase (CPT) 1, carnitine/acylcarnitine translocase and CPT 11. There is controversy as to the location of CPT I and 11 in the mitochondria and to whether CPT I and CPT II are the same enzyme protein (Bieber & Farrell, 1983; Murthy & Pande, 1987 ; Ramsay er a/.. 1987).
Several patients with deficiencies of CPT have been described, although the conditions under which the enzyme has been assayed have been unsatisfactory in many cases (for discussion see Zierz 81 Engel, 1085; Sherratt et a/., 1988). Few attempts have been made to determine whether CPT I and/or CPT 11 have been involved in these defects. The majority of patients present with exercise-induced muscle pain (DiMauro cr a/., 1980), the CPT deficiency being limited t o skeletal muscle. However, one family has been described in which severe hypoglycaemia in infancy occurred (Bougneres et a/., 198 1 ). One person in this family was investigated and was found to have no detectable CPT activity in a liver extract. It is not known whether there are different tissue isoforms of the enzyme which account for the diffcrcnt clinical presentations.
Zierz 81 Engel (1985) have made an attempt to elucidate the nature of the enzyme defect by studying seven patients with exercise-induced muscle pain and proven CPT deficiency. The results suggested that the CPT dcficiency in thesc seven cases was caused by the altered kinctic properties of a mutant enzyme.
AcyI-CoA ci'ehyirogeriuse deficiency, There has been considerable recent interest in defects of the acyl-CoA dehydrogenases particularly because of the possibility that some of the defects may be important causes of the cot death syndrome (Howat er al., 1985) . There are probably three straight-chain acyl-CoA dehydrogenases in human tissues (short-chain, medium-chain and long-chain) ( The definitive diagnosis of defects of acyl-CoA dehydrogenases depends on the assay of the enzyme activity in human tissues. Short-chain, medium-chain and long-chain acyl-CoA dehydrogenase activities are measured using nbutyryl-CoA (C4), octanoyl-CoA (C,) and palmitoyl-CoA (C ,,,), respectively, as substrates. A dye-reduction assay is satisfactory for mitochondrial fractions from human tissues (Turnbull et a/., 1984) , but an electron transfer flavoprotein (ETF )-linked assay, although technically demanding, is both more specific and sensitive (Frerman & Goodman, 1 9 8 5~) . This latter assay has also been used with cell homogenates. lmmunoprecipitation experiments using human tissue fractions (cultured fibroblasts, liver mitochondria and skeletal muscle mitochondria) have suggested that mediumchain acyl-CoA dehydrogenase is responsible for 50% of the activity involved in the dehydrogenation of butyryl-CoA (Hale et a/., 1986; Amendt et a/., 1987; I. M. Shepherd & D. M. Turnbull, unpublished work). These experiments used an ETF-linked assay (Frerman & Goodman, 1985a) , but determination of acyl-CoA dehydrogenase activity using a dye-reduction assay with phenazine ethosulphate as an intermediate electron acceptor reveals different substrate specificities for the short-chain and medium-chain acyl-CoA dehydrogenases (I. M. Shepherd & D. M. Turnbull, unpublished work) . It is important to be aware of these problems when making a diagnosis of short-chain acyl-CoA dehydrogenase deficiency.
Four patients with a deficiency of short-chain acyl-CoA dehydrogenase have been described. Turnbull et a/. ( 1984) described a 46-year-old woman with proximal muscle weakness and muscle pain. There was a low activity of dehydrogenation of short-chain acyl-CoA esters in skeletal muscle mitochondrial extracts prepared from this patient. Short-chain acyl-CoA dehydrogenase activity in cultured skin fibroblasts from this patient was normal and there was a large ketotic response to fasting, indicating that the liver enzyme was also normal. Coates er ul. (1986) described an infant who presented with failure to thrive, hypotonia, developmental delay, progressive muscle weakness and microcephaly. Short-chain acyl-CoA dehydrogenase activity was low in fibroblasts from this patient. Amendt e t a / . (1987) have recently described two children with short-chain acylCoA dehydrogenase deficiency. 'The first child presented with a severe metabolic acidosis. Following recovery from this initial episodc she has grown and developed normally. The second child died on the sixth day of life with hypotonia, coma and a metabolic acidosis. The activity of short-chain acyl-CoA dehydrogenasc was low in cultured skin fibroblasts from both of thesc patients, particularly after the mediumchain enzyme had been selectively immunoprecipitated.
Medium-chain acyl-CoA dehydrogenase dcficiency presents in various ways including an acute fulminating illness (Duran et 1985) and systemic carnitine deficiency (Zicrz er a/., 1986). Since thc defect was first characterized, at least 30 patients with this disease havc been confirmed (Finocchiaro et a/., 1987) .
Investigations are now in progress in many laboratories to try to determine the molecular basis of these deficiencies, particularly the most frequently described medium-chain acyl-CoA dehydrogenase deficiency. Ikeda et a/. ( 1986) have studied the medium-chain acyl-CoA dehydrogenase in fibroblasts from 13 patients. While the residual activity ranged from 5 to 12% of the mean value of fibroblasts from normal controls, the variant medium-chain acyl-CoA dehydrogenase in the cells from these patients was indistinguishable from normal human medium-chain acyl-CoA dehydrogenase on the basis of molecular size. This suggests that in their patients the enzyme deficiency is probably due to a point mutationjs) in the medium-chain acyl-CoA dehydrogenase gene. Matsubara eta/. ( 1986) have described the isolation of partial complementary DNAs (cDNA) encoding rat and human medium-chain acyl-CoA dehydrogenase. Using the cloned human cDNA as a probe, they assigned the gene for medium-chain acyl-CoA dehydrogenase to the short arm of human chromosome 1, band p3 1. In the future, cDNA cloning of medium-chain acyl-CoA dehydrogenase will provide a valuable tool for the molecular study of medium-chain acylCoA dehydrogenase and its genetic deficiency in man.
Long-chain acyl-CoA dehydrogenase deficiency has only been reported in a few cases. Hale et a/. (1985) described three children who presented in early childhood with hypoglycaemia, hepatomegaly, cardiomyopathy and muscle weakness. Naylor et al. (1980) reported two siblings with intermittent hypoglycaemia, lethargy and coma, who were subsequently shown to have long-chain acyl-CoA dehydrogenase deficiency.
3-Oxoacy/-CoA thiolases. There are four 3-oxoacyl-CoA thiolases in mammalian cells which have different subcellular locations and substrate specificities (Middleton, 1973; Krahling & Tolbert, 1981) . The cytoplasmic enzyme is involved in cholesterogenesis, is specific for acetoacetyl-CoA and is not activated by K + . The peroxisomal enzyme and one of the mitochondrial enzymes have a broad substrate speciVol. 16 ficity. The other mitochondrial thiolase is activated by K + and is specific for aeetoacetyl-CoA and methylaeetoaeetylCoA. The mitochondrial thiolase of broad substrate specificity is responsible for thiolysis of 3-oxoacyl-CoA esters generated during P-oxidation and no dcfects of this enzyme have been described. The other mitochondrial enzyme is primarily involved in ketone body metabolism and isoleucine degradation. Patients with a defect in this enzyme present with a metabolic acidosis and hypoglycaemia (Leonard et a/., I Y87). In the majority of patients the defect is associated with the urinary excretion of metabolites derived from isoleucine (2-methylacetoacetate, 2-methyl-3-hydroxybutyrate and tiglylglycine) in addition to 3-hydroxybutyrate. The diagnosis is confirmed by measuring 3-oxoaeyl-CoA thiolase activity using acetoaeetyl-CoA as substrate in the presence and absence of K + ions, and using 2-methylacetoacetyl-CoA as substrate (Middleton & Bartlett, 1983) . It has been suggested that there is an hepatic and an extra-hepatic form of the enzyme, and that some of the variations in clinical presentation and urinary metabolite excretion are due to the involvement of the different isoenzvmes (Leonard el a/., 1987) .
Gkturic ucidwiu iype 11. The enzyme defect in this disorder involves either ETF or electron transfer flavoprotein: ubiquinone oxidoreductase (ETF-QO). ETF and ETFQO mediate electron transfer to the ubiquinone pool from eight FAD-linked dehydrogenases (Frerman, 1988) . The degradation of amino acids is inhibited in this condition, in addition to impaired fatty acid oxidation. Glutaric aciduria type II usually presents in one of three ways, each presentation being consistent within a family (Goodman & Frerman, 1984) . Thus, there is a group of patients who have severe neonatal symptoms of hypoglycaemia and acidosis associated with congenital abnormalities. In the second group, the onset is also in the neonatal period, but there are n o eongenital abnormalities. The third group comprises patients who present later in life. Howcver, the age of onset, the initial symptoms, the clinical findings and the tissues involved vary considerably in this latter group.
Frerman & Goodman ( l 9 8 S h ) showed that cultured skin fibroblasts from three unrelated glutaric aciduria type 11 patients had no detectable ETF-QO catalytic activity and no immunologically detectable ETF-QO. Fibroblasts from the parents of two of these patients had ETF-QO activity intermediate between the control fibroblasts and the patient's fibroblasts, indicating that the mode of inheritance was autosoma1 recessive. Fibroblasts from two other patients with severe glutaric aciduria type I1 had normal ETF-QO activities and antigen, but were severely deficient in immunoreactive ETF (Frerman & Goodman, 1985a ,h). lkeda et al. (1986 studied the biosynthesis of ETF in cultured skin fibroblasts from eight patients, and found a defect of the asubunit of ETF in three of the cell lines. The defect in the a-subunit manifested itself in three different ways, suggesting that these defects result from three different variant alleles.
C'onclirsiori
Defects of mitochondrial /3-oxidation are a very important group of inborn errors of metabolism and significant advances in this field have been made during the last few years. It is likely that defects involving the other enzymes of /3-oxidation will be described. However, the investigation of these patients requires a combination of clinical and biochemical skills which can be provided only in a few centres.
The treatment of defects of fatty acid oxidation includes the careful monitoring of patients, especially children, for the development of hypoglyeaemia, and it is essential that the risks, prevention and management of hypoglycaemia are explained to the family. Children should not be starved and must be admitted for careful monitoring if they become unwell, particularly with a febrile illness with vomiting. A low fat diet with regular carbohydrate rich meals should help prevent hypoglycaemia. The administration of pharmaeological doses of riboflavin has proved to be effective in some patients with glutaric aciduria type I1 (de Visser et a/., 1986). Since the biochemical defect is expressed in amniocytes, the prenatal diagnosis of acyl-CoA dehydrogenase deficiency is possible (Bennett el ul., 1987) . Recent elucidation of the biochemical defect in glutaric aciduria type I1 suggests that prenatal diagnosis may also be possible in this disorder.
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